



SRO-MAIN CAMPUS
401 BICENTENNIAL WAY
SANTA ROSA CA 95403-2149
Encounter Record

HARDEMAN, EDWIN
MRN: [REDACTED]
DOB: [REDACTED], Sex: M
Enc. Date: 02/19/15

Office Visit
2/19/2015 Office Visit

Visit Information

	Provider	Department	Encounter #
2/19/2015 10:10 AM	JEFFREY ZHENG-SHENG YE MD	Sro-Onc* >Main Campus	387949124

Allergies as of 2/19/2015

Reviewed On: 2/6/2015 By: Firmes, Randy H (M.A.)

Allergen	Noted	Reaction Type	Reactions
No Known Drug Allergies 2001-11-27, ADMIT ORDER	11/27/2001		

Immunizations Administered on Date of Encounter - 2/19/2015

Never Reviewed

No immunizations on file.

Reason For Encounter History

User	Date & Time
Wilson, Cyndi (M.A.)	2/19/2015 10:11 AM
Reason For Encounter	
CONSULTATION Comment: ONCOLOGY CONSULT	

Diagnoses

DIFFUSE LARGE B-CELL LYMPHOMA - Primary
LIVER CIRRHOSIS
HX OF HEPATITIS C



Vitals

BP	Pulse	Ht	Wt	BMI
151/86 mmHg	62	5' 9"	213 lb (96.616 kg)	31.44 kg/m2

Flowsheet (all recorded)

Encounter Vitals

	02/19/15 1011
Enc Vitals	
BP	151/86 mmHg -CW
Pulse	62 -CW
Wt (qms)	213 lb (96.616 kg) -CW
Height	5' 9" -CW

User Key

(r) = User Recd, (t) = User Taken, (c) = User Cosigned

Initials	Name	Effective Dates
CW	Wilson, Cyndi (M.A.)	12/14/14 - 09/15/15

Encounter Information

	Provider	Department	Center
2/19/2015 10:10 AM	JEFFREY ZHENG-SHENG YE MD	Sro-Onc* >Main Campus	SROA

Progress Notes

Ye, Jeffrey Zheng-Sheng (M.D.) at 2/19/2015 12:14 PM

Author Type: Physician Status: Signed

CC: Diffuse large B cell lymphoma

HPI: Edwin Hardeman is a 66 Y male referred by Dr. Turley

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA

TRIAL EXHIBIT 45

Case No. 3:16-cv-0525-VC

Date Entered _____

By _____
Deputy Clerk



SRO-MAIN CAMPUS
 401 BICENTENNIAL WAY
 SANTA ROSA CA 95403-2149
 Encounter Record

HARDEMAN, EDWIN
 MRN: [REDACTED]
 DOB: [REDACTED] Sex: M
 Enc. Date: 02/19/15

Progress Notes (continued)

Ye, Jeffrey Zheng-Sheng (M.D.) at 2/19/2015 12:14 PM (continued)

Version 1 of 1

Felt non tender lumps on the right neck after Christmas that persisted for several weeks. FNA (1/28/2015) showed necrotic cells. Core biopsy 2/6/2015 showed diffuse large B cell lymphoma, Ki67 = 80% of the large cells. The neckmasses have not changed in size, or even become softer since he first felt them. Patient is otherwise asymptomatic except chronic fatigue; no recent exacerbation. Denies night sweats, fever, or weight loss.

Hx of hepC s/p IFN therapy in 2005. Recent viral screening showed hx of HepB exposure (HBsg/Ab-; HBcAb+)

Liver cirrhosis documented by sonogram. Liver reserve excellent

Wt Readings from Last 3 Encounters:

02/19/15 213 lb (96.616 kg)
 01/28/15 215 lb 9.6 oz (97.796 kg)
 12/26/14 218 lb (98.884 kg)

Patient Active Problem List:

- HX OF HEPATITIS C
- CIRRHOSIS OF LIVER
- HYPERTENSION
- LEFT BRANCH RETINAL VEIN OCCLUSION
- KNEE PAIN
- SEBORRHEIC KERATOSIS
- LIPOMA
- BILAT CATARACT
- BILAT OPEN ANGLE GLAUCOMA
- BPH (BENIGN PROSTATIC HYPERTROPHY)
- ACTINIC KERATOSIS

Reviewed lab results

ROS: General - well
 ENT & Eyes - no discharge or epistaxis
 CV - no palpitation, chest pain, or DOE
 Respiratory - no cough, dyspnea, or hemoptysis
 GI - no nausea, vomiting, or diarrhea

Allergy

Current Outpatient Prescriptions

Medication	Sig
• Latanoprost (XALATAN) 0.005 % Opht Drop	Instill 1 drop into each eye daily at bedtime for glaucoma
• Dorzolamide-Timolol (COSOPT) 2-0.5 % Opht Drop	Instill 1 drop into each eye 2 times a day for glaucoma
• Hydrochlorothiazide (ESIDRIX/HYDRODIURIL) 25 mg Oral Tab	Take 1 tablet orally daily
• Lisinopril (PRINIVIL/ZESTRIL) 10 mg Oral Tab	Take 4 tablets orally daily

No current facility-administered medications for this visit.



SRO-MAIN CAMPUS
 401 BICENTENNIAL WAY
 SANTA ROSA CA 95403-2149
 Encounter Record

HARDEMAN, EDWIN
 MRN: [REDACTED]
 DOB: [REDACTED], Sex: M
 Enc. Date: 02/19/15

Progress Notes (continued)

Ye, Jeffrey Zheng-Sheng (M.D.) at 2/19/2015 12:14 PM (continued)

Version 1 of 1

Physical exam: A&O, NAD
 BP 151/86 | Pulse 62 | Ht 5' 9" | Wt 213 lb (96.616 kg) | BMI 31.44 kg/m2
 Lymph - 2 right cervical nodes (3-4 cm each); no other palpable adenopathy
 ENT/Eyes/Neck - conjunctivae non-injected; no oral thrush; no JVD; neck supple
 COR - regular rate & rhythm; no murmur; no gallop
 Respiratory - Lungs clear; no rales; no wheezes
 Abdomen - soft, NT ND, no organomegaly or mass
 Skin - intact; no rash
 Neuro - alert; normal gait
 Extremity - no edema or cyanosis

Basename	Value	Date/Time
• WBC	6.7	01/28/2015
• HCT	43.7	01/28/2015
• HGB	14.9	01/28/2015
• PLT	169	01/28/2015
• CHOL	156	12/30/2014
• HDL	34	12/30/2014
• LDL CALC	81	12/30/2014
• LDL DIRECT	104	11/03/2005
• TRIG	204	12/30/2014
• ALT	21	01/28/2015
• AST	18	12/30/2014
• CREAT	0.89	01/28/2015
• GFR-AFRAM	>60	01/28/2015
• GFR NONAFR AMER	>60	01/28/2015
• GFR-NONAFRAM	>60	07/13/2011
• K	4.7	01/28/2015
• NA	138	01/28/2015
• CO2	30	07/18/2007
• CL	108	07/18/2007
• TSH	3.20	01/28/2015
• PSA	0.4	07/13/2011
• INR	1.1	01/28/2015
• INR	1.1	12/30/2014
• INR	1.1	07/13/2011
• GLUC FAST	92	12/30/2014
• GLUC	108	01/28/2015
• URIC	5.2	12/14/2005

Assessment and Plan: DLBCL, ki67 = 80%; PET scan scheduled on Friday 2/20

Discussed diagnosis and staging driven approach in treatment. Bone marrow biopsy scheduled for 2/23 when his wife can come together. I recommended R-CHOP possible followed by radiation if early stage disease is diagnosed by PET and BMBx. Discussed the benefits, side effects, and precautions for these



SRO-MAIN CAMPUS
 401 BICENTENNIAL WAY
 SANTA ROSA CA 95403-2149
 Encounter Record

HARDEMAN, EDWIN
 MRN: [REDACTED]
 DOB: [REDACTED], Sex: M
 Enc. Date: 02/19/15

Progress Notes (continued)

Ye, Jeffrey Zheng-Sheng (M.D.) at 2/19/2015 12:14 PM (continued)

Version 1 of 1

drug. Patient was aware that rare, atypical, and potentially serious or fatal side effects can occur with chemotherapy drugs. Patient asked relevant questions that I answered to her satisfaction

We specifically discussed two additional concerns in his case:

-The impact of hepC liver cirrhosis on clinical tolerance and marrow reserve. His liver functional reserve is excellent so I do not recommend upfront dose reduction. Will need to aggressively support with neupogen. Interval between cycles may need to be extend to 4 weeks

-HepB/C reactivation from rituximab: will monitor both diseases through the treatment. I recommended prophylactic lamivudine 150 mg QD

Patient asked many relevant questions and

Electronically signed by Ye, Jeffrey Zheng-Sheng (M.D.) on 2/19/2015 1:27 PM

Patient Secure Message

No messages in this encounter

Progress Notes

Author	Status	Last Editor	Updated	Created
Ye, Jeffrey Zheng-Sheng (M.D.)	Signed	Ye, Jeffrey Zheng-Sheng (M.D.)	2/19/2015 1:27 PM	2/19/2015 12:14 PM

CC: Diffuse large B cell lymphoma

HPI: Edwin Hardeman is a 66 Y male referred by Dr. Turley

Felt non tender lumps on the right neck after Christmas that persisted for several weeks. FNA (1/28/2015) showed necrotic cells. Core biopsy 2/6/2015 showed diffuse large B cell lymphoma, Ki67 = 80% of the large cells. The neckmasses have not changed in size, or even become softer since he first felt them. Patient is otherwise asymptomatic except chronic fatigue; no recent exacerbation. Denies night sweats, fever, or weight loss.

Hx of hepC s/p IFN therapy in 2005. Recent viral screening showed hx of HepB exposure (HBsg/Ab-; HBcAb+)

Liver cirrhosis documented by sonogram. Liver reserve excellent

Wt Readings from Last 3 Encounters:

02/19/15 213 lb (96.616 kg)
 01/28/15 215 lb 9.6 oz (97.796 kg)
 12/26/14 218 lb (98.884 kg)

Patient Active Problem List:

- HX OF HEPATITIS C
- CIRRHOSIS OF LIVER
- HYPERTENSION
- LEFT BRANCH RETINAL VEIN OCCLUSION



SRO-MAIN CAMPUS
 401 BICENTENNIAL WAY
 SANTA ROSA CA 95403-2149
 Encounter Record

HARDEMAN, EDWIN
 MRN: [REDACTED]
 DOB: [REDACTED], Sex: M
 Enc. Date: 02/19/15

KNEE PAIN
 SEBORRHEIC KERATOSIS
 LIPOMA
 BILAT CATARACT
 BILAT OPEN ANGLE GLAUCOMA
 BPH (BENIGN PROSTATIC HYPERTROPHY)
 ACTINIC KERATOSIS

Reviewed lab results

ROS: General - well
 ENT & Eyes - no discharge or epistaxis
 CV - no palpitation, chest pain, or DOE
 Respiratory - no cough, dyspnea, or hemoptysis
 GI - no nausea, vomiting, or diarrhea

Allergy

Current Outpatient Prescriptions

Medication	Sig
• Latanoprost (XALATAN) 0.005 % Opht Drop	Instill 1 drop into each eye daily at bedtime for glaucoma
• Dorzolamide-Timolol (COSOPT) 2-0.5 % Opht Drop	Instill 1 drop into each eye 2 times a day for glaucoma
• Hydrochlorothiazide (ESIDRIX/HYDRODIURIL) 25 mg Oral Tab	Take 1 tablet orally daily
• Lisinopril (PRINIVIL/ZESTRIL) 10 mg Oral Tab	Take 4 tablets orally daily

No current facility-administered medications for this visit.

Physical exam: A&O, NAD

BP 151/86 | Pulse 62 | Ht 5' 9" | Wt 213 lb (96.616 kg) | BMI 31.44 kg/m²
 Lymph - 2 right cervical nodes (3-4 cm each); no other palpable adenopathy
 ENT/Eyes/Neck - conjunctivae non-injected; no oral thrush; no JVD; neck supple
 COR - regular rate & rhythm; no murmur; no gallop
 Respiratory - Lungs clear; no rales; no wheezes
 Abdomen - soft, NT ND, no organomegaly or mass
 Skin - intact; no rash
 Neuro - alert; normal gait
 Extremity - no edema or cyanosis

Basename	Value	Date/Time
• WBC	6.7	01/28/2015
• HCT	43.7	01/28/2015
• HGB	14.9	01/28/2015
• PLT	169	01/28/2015
• CHOL	156	12/30/2014
• HDL	34	12/30/2014
• LDL CALC	81	12/30/2014
• LDL DIRECT	104	11/03/2005
• TRIG	204	12/30/2014
• ALT	21	01/28/2015



SRO-MAIN CAMPUS
 401 BICENTENNIAL WAY
 SANTA ROSA CA 95403-2149
 Encounter Record

HARDEMAN, EDWIN
 MRN [REDACTED]
 DOB [REDACTED], Sex: M
 Enc. Date: 02/19/15

AST	18	12/30/2014
• CREAT	0.89	01/28/2015
• GFR-AFRAM	>60	01/28/2015
• GFR NONAFR AMER	>60	01/28/2015
• GFR-NONAFRAM	>60	07/13/2011
• K	4.7	01/28/2015
• NA	138	01/28/2015
• CO2	30	07/18/2007
• CL	108	07/18/2007
• TSH	3.20	01/28/2015
• PSA	0.4	07/13/2011
• INR	1.1	01/28/2015
• INR	1.1	12/30/2014
• INR	1.1	07/13/2011
• GLUC FAST	92	12/30/2014
• GLUC	108	01/28/2015
• URIC	5.2	12/14/2005

Assessment and Plan: DLBCL, ki67 = 80%; PET scan scheduled on Friday 2/20

Discussed diagnosis and staging driven approach in treatment. Bone marrow biopsy scheduled for 2/23 when his wife can come together. I recommended R-CHOP possible followed by radiation if early stage disease is diagnosed by PET and BMBx. Discussed the benefits, side effects, and precautions for these drug. Patient was aware that rare, atypical, and potentially serious or fatal side effects can occur with chemotherapy drugs. Patient asked relevant questions that I answered to her satisfaction

We specifically discussed two additional concerns in his case:

- The impact of hepC liver cirrhosis on clinical tolerance and marrow reserve. His liver functional reserve is excellent so I do not recommend upfront dose reduction. Will need to aggressively support with neupogen. Interval between cycles may need to be extend to 4 weeks
- HepB/C reactivation from rituximab: will monitor both diseases through the treatment. I recommended prophylactic lamivudine 150 mg QD

Patient asked many relevant questions and

Level of Service

OUTPT NEW LEVEL 5 [99205B]

Order

ECHOCARDIOGRAM, TRANSTHORACIC,
 TRANSESOPHAGEAL AND STRESS [227256] (Order
 564626389)

All Orders

Order Information

Date	Department	Ordering/Authorizing
2/19/2015	ONCOLOGY	Ye, Jeffrey Zheng-Sheng (M.D.)